About Hydroxyacid-oxoacid transhydrogenase, mitochondrial
Hydroxyacid-oxoacid transhydrogenase, mitochondrial (ADHFE1) is a protein
from Homo sapiens identified by UniProt accession
Q8IWW8, 467 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | Hydroxyacid-oxoacid transhydrogenase, mitochondrial |
| UniProt accession | Q8IWW8 |
| Gene | ADHFE1 |
| Organism | Homo sapiens |
| Length | 467 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (68)
Diseases linked to this target (Open Targets).
- blood metabolite measurement · score 0.31
- body mass index · score 0.23
- body weight · score 0.17
- waist circumference · score 0.16
- PHF-tau measurement · score 0.15
- body height · score 0.15
- appendicular lean mass · score 0.09
- cancer · score 0.08
- daytime rest measurement · score 0.08
- lean body mass · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IWW8-F1 | alphafold | PREDICTED | 92.87 | — |
Amino-acid sequence (467 residues)
MAAAARARVA YLLRQLQRAA CQCPTHSHTY SQAPGLSPSG KTTDYAFEMA VSNIRYGAAV TKEVGMDLKN MGAKNVCLMT DKNLSKLPPV QVAMDSLVKN GIPFTVYDNV RVEPTDSSFM EAIEFAQKGA FDAYVAVGGG STMDTCKAAN LYASSPHSDF LDYVSAPIGK GKPVSVPLKP LIAVPTTSGT GSETTGVAIF DYEHLKVKIG ITSRAIKPTL GLIDPLHTLH MPARVVANSG FDVLCHALES YTTLPYHLRS PCPSNPITRP AYQGSNPISD IWAIHALRIV AKYLKRAVRN PDDLEARSHM HLASAFAGIG FGNAGVHLCH GMSYPISGLV KMYKAKDYNV DHPLVPHGLS VVLTSPAVFT FTAQMFPERH LEMAEILGAD TRTARIQDAG LVLADTLRKF LFDLDVDDGL AAVGYSKADI PALVKGTLPQ ERVTKLAPCP QSEEDLAALF EASMKLY
Explore Hydroxyacid-oxoacid transhydrogenase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets